SCHEMBL34461705

SCHEMBL34461705

O=c1c2[nH]ccc2n(CCO)c2nnc(-c3ccccc3[N+](=O)[O-])n12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 3/20 0.46
▸ HSD11B1 P28845 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ GFER P55789 1/20 0.35
▸ CFTR P13569 1/20 0.35
▸ MAOB P27338 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ TP53 P04637 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ F2 P00734 1/20 0.32
▸ C1R P00736 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34461745 0.87 ADORA2A (0.41) ADORA2AHSD11B1ALDH1A1GFERCFTR
SCHEMBL34461787 0.87 ADORA2A (0.42) ADORA2AHSD11B1ALDH1A1GFERCFTR
SCHEMBL34461749 0.85 ADORA2A (0.41) ADORA2AHSD11B1ALDH1A1GFERCFTR
SCHEMBL34461736 0.78 MEN1 (0.40) ADORA2AALDH1A1MAPTMEN1KMT2A
SCHEMBL34461733 0.67 ADORA2A (0.38) ADORA2AALDH1A1MAPTPOLBATM
SCHEMBL21530648 0.63 ADORA2A (1.00) ADORA2AALDH1A1SMN1; SMN2
SCHEMBL20552683 0.60 ALDH1A1 (0.47) ALDH1A1MAOBTDP1MAPTMEN1
SCHEMBL34461772 0.59 CYP1A2 (0.35) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL21530652 0.58 ADORA2A (0.72) ADORA2AALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL21530667 0.58 ADORA2A (1.00) ADORA2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2026-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS WRN, POLR1A, REV1 ADORA2A 586/4885HSD11B1 373/4885ALDH1A1 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback